Related Experiment Video

Updated: Jul 7, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with

Jing-Zhi Guan1, Naoki Tamasawa, Hiroshi Murakami

  • 1Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine.

Journal of Atherosclerosis and Thrombosis
|February 14, 2008
PubMed

Insights

Simvastatin treatment improved reverse cholesterol transport (RCT) in type 2 diabetic patients with hyperlipidemia. This suggests simvastatin may enhance RCT, potentially benefiting patients with reduced cholesterol efflux.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Endocrinology

Background:

  • Apolipoprotein A-I (ApoA-I) and high-density lipoprotein (HDL) are crucial for cellular cholesterol efflux in reverse cholesterol transport (RCT).
  • Low HDL cholesterol (HDL-C) is a hallmark of atherogenic dyslipidemia in type 2 diabetes mellitus (T2DM).

Purpose of the Study:

  • To evaluate plasma lipid levels and RCT-related factor expression in T2DM patients.
  • To investigate the effects of simvastatin on RCT in T2DM patients with hyperlipidemia.

Main Methods:

  • Messenger RNA (mRNA) expression of key RCT factors (LXR alpha, ABCA1, SR-B1, ApoE, ApoA-1, caveolin, CETP) was analyzed using RT-PCR in circulating mononuclear cells.
  • T2DM patients were categorized into normolipidemic, hyperlipidemic, and simvastatin-treated hyperlipidemic groups, compared with a healthy control group.

Main Results:

  • Simvastatin significantly increased plasma ApoA-I levels compared to other groups.
  • Simvastatin treatment enhanced mRNA expression of LXR alpha, ABCA1, and ApoA-I compared to untreated hyperlipidemic or control groups.

Conclusions:

  • Reverse cholesterol transport may be impaired in type 2 diabetic patients with hyperlipidemia.
  • Simvastatin demonstrates potential to improve RCT in this patient population, suggesting a therapeutic benefit.
Abstract

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.